Core Viewpoint - Citigroup's research report indicates that recent measures released by Shanghai's financial and healthcare regulatory bodies aim to promote the high-quality development of commercial health insurance, which is expected to gradually expand nationwide [1] Group 1: Industry Impact - Commercial insurance is seen as a new financial resource for the healthcare system, which should help increase the usage of drugs, medical devices, diagnostics, and other medical procedures [1] - Innovative products are anticipated to benefit significantly from these developments [1] Group 2: Key Beneficiaries - Major beneficiaries identified within Citigroup's research include: - Heng Rui Medicine - China National Pharmaceutical Group - Innovent Biologics - Mindray Medical - Ping An Good Doctor [1]